Biocartis launches CE-marked IVD RAS liquid biopsy tests developed under partnership with Merck KGaA, Darmstadt, Germany. The Idylla™ ctRAS liquid biopsy tests detect RAS mutations in patients with...
Read More »MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced a partnership to develop ...
Read More »Biocartis Group NV: Biocartis launches second liquid biopsy assay
Assay co-developed with Merck for detection of KRAS mutations, operating directly on 1 ml blood plasma Biocartis Group NV (‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the launch of its second liquid biopsy assay, the Idylla(TM) ...
Read More »